3rd Annual Leadership Summit on the Road to Interoperability

Jul 21st, 2008Jul 22nd, 2008
Boston, MA
US
https://www.worldcongress.com
Third annual leadership summit on "the road to interoperability" -- driving health information exchange to the next level to provide efficient, effective, and equitable patient-centered care.
Latest in Home
A Ibrain
PET reveals brain receptor deficits in schizophrenia
June 4, 2026
Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.
MRI finds perfusion defects across a range of lung impairments
June 4, 2026
AI for CT & PET/CT Imaging
Sponsored
AI for CT & PET/CT Imaging
June 4, 2026
Lab Equipment Drug Manufacturing
Radiopharmaceutical manufacturers report uneven FDA inspections
June 4, 2026
More in Home
PET reveals brain receptor deficits in schizophrenia
By Will Morton
The study confirms that deficits in M1 receptor are present in a subgroup of schizophrenia patients.
June 4, 2026
A Ibrain
MRI finds perfusion defects across a range of lung impairments
By Kate Madden Yee
Impaired lung function is associated with increased pulmonary perfusion defects detectable by a particular MRI technique.
June 4, 2026
Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.
AI detects lung cancer nodules well but shows low specificity
By Kate Madden Yee
The finding suggests the models offer “a potential role as adjunctive tools for ruling out malignancy” rather than classifying it.
June 4, 2026
Am 2020 06 26 16 29 2945 Cancer Lung 400
Radiopharmaceutical manufacturers report uneven FDA inspections
By Liz Carey
RMTA lays out radiopharmaceutical regulatory and payment policy issues.
June 4, 2026
Lab Equipment Drug Manufacturing
AI-driven cardiac PET attenuation correction shows promise
By Kate Madden Yee
The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.
June 3, 2026
Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
ASCO: With help from AI, interventions boost lung cancer screening
By Erik L. Ridley
Screening rate increased sharply over six years at the 17-hospital health system.
June 3, 2026
Asco Thumb
Philips Interactive Multimedia Reporting: Where Insight Meets Impact
By Philips Healthcare Informatics
Radiology is no longer just about what you see, it’s about how effectively you communicate it.
June 2, 2026
2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static
Radiologists estimate time savings with advanced radiology reports
By Liz Carey
Survey-driven insights into the impact of interactive multimedia reporting, plus practical tips to take forward when planning to implement a system.
June 2, 2026
David Vining Md Anderson Longitudinal Record Imr 2026
Interactive multimedia radiology reporting improves physician consults
By Liz Carey
Radiologists and referring physicians who are successfully using IMR advanced radiology reporting share their perspectives.
June 2, 2026
Adobe Stock 1568461586 Fizkes
SNMMI: PET reveals new brain activity in multiple sclerosis
By Will Morton
Understanding how and where certain brain connections are lost can help explain the symptoms patients experience.
June 2, 2026
Representative SV2A PET images comparing synaptic density in healthy and disease states. The left panel shows F-18 SynVesT-1 PET distribution volume (VT) maps of the brain and spinal cord in a naïve control mouse and a mouse with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The right panel shows Cu-11 UCB-J PET images of the brain of a 46-year-old male healthy control (left) and 43-year-old female MS patient (right).
SNMMI: New PET platform guides real-time bone cancer margin assessment
By Kate Madden Yee
The approach has the potential to reshape surgical practice for osteosarcoma by allowing for precise tumor resection.
June 2, 2026
(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.
Page 1 of 231
Next Page